Clinical Trial Results: A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers [Phase 1]

View source ↗

Summary

Phase I, single-arm dose-escalation study evaluating safety and tolerability of Orialpha (BD-C) in healthy adult volunteers; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Orialpha (BD-C) (Orialpha)

Snippet

Sponsor: Oriplantee Company Limited | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2026-07-16